Peek Under The Hood: XBI Has 36% Upside
July 02, 2020 at 08:41 AM EDT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $152.93 per unit.